Coherus Oncology (CHRS) Revenue Growth (1y) (2014 - 2026)
Coherus Oncology (CHRS) Revenue Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 96.43% |
| 10 | Coherus Oncology | 199.82 Mn | 32.78 Mn | 8.50 Mn | 61.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.99% |
| Dec 31, 2025 | 64.85% |
| Sep 30, 2025 | 91.19% |
| Jun 30, 2025 | -0.41% |
| Mar 31, 2025 | 229.25% |
| Dec 31, 2024 | -91.55% |
| Sep 30, 2024 | -91.88% |
| Jun 30, 2024 | -82.46% |
| Mar 31, 2024 | -92.88% |
| Dec 31, 2023 | 101.81% |
| Sep 30, 2023 | 64.16% |
| Jun 30, 2023 | -2.39% |
| Mar 31, 2023 | -46.04% |
| Dec 31, 2022 | -38.17% |
| Sep 30, 2022 | -44.94% |
| Jun 30, 2022 | -31.37% |
| Mar 31, 2022 | -27.60% |
| Dec 31, 2021 | -33.57% |
| Sep 30, 2021 | -27.35% |
| Jun 30, 2021 | -35.40% |